New imaging tracer could spot kidney cancer without a needle
NCT ID NCT06090331
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program gives patients with kidney masses access to a radioactive tracer called 89Zr-DFO-girentuximab, which is used with a PET/CT scan to detect clear cell renal cell carcinoma (a common kidney cancer) without surgery. The tracer attaches to a protein (CAIX) often found on these cancer cells, making them visible on the scan. The goal is to provide a non-invasive diagnostic option for patients who have suspicious kidney masses seen on standard CT or MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 89Zr-DFO-girentuximab (a radioactive tracer for PET/CT imaging)
- What this could lead to
- If successful, this imaging method could provide a non-invasive way to detect clear cell renal cell carcinoma, potentially reducing the need for biopsies.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on effectiveness and safety are limited. The tracer may not accurately distinguish all cancer types, and radiation exposure is a risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arkansas Urology
Little Rock, Arkansas, 72211, United States
-
Austin Radiological Association
Austin, Texas, 78705, United States
-
Biogenix Molecular
Miami, Florida, 33165, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Indiana University
Bloomington, Indiana, 47405, United States
-
Kansas University Medical Center
Kansas City, Kansas, 66103, United States
-
Kettering Health Main Campus
Kettering, Ohio, 45429, United States
-
M Health Fairview/ University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
MD Anderson Cancer Center
Houston, Texas, 77054, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Munson Medical Center
Traverse City, Michigan, 49684, United States
-
Sarasota Memorial Health Care System
Sarasota, Florida, 34243, United States
-
Stanford Urologic Cancer Program
Palo Alto, California, 94304, United States
-
UCLA
Los Angeles, California, 90095, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
United Theranostics
Glen Burnie, Maryland, 21061, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Florida College of Medicine Jacksonville
Jacksonville, Florida, 32209, United States
-
Urology Associates, PC
Nashville, Tennessee, 37209, United States
-
Urology San Antonio
San Antonio, Texas, 78229, United States
-
Xcancer
Omaha, Nebraska, 68130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
- Personalized vaccine trains immune system to attack kidney cancer blood vessels